Cancer Genetics launches CALR mutation analysis test Cancer Genetics has launched a genetic diagnostic test for detecting mutations in the calreticulin gene. This test helps physicians identify patients with certain types of myeloproliferative neoplasms, which are blood cancers that have the potential to evolve into acute leukemia. CGI is one of the first laboratories in the U.S. to offer this test under both CLIA and NY-State Approvals. Patients with the CALR mutation are understood to have more favorable disease outcomes as well as longer overall survival in comparison to patients who possess other biomarkers. Therefore, the results of the test could have implications in predicting a patient's outlook.